SPOTLIGHT: Talabostat heads to Phase III


Point Therapeutics says it will push Talabostat for pancreatic cancer into Phase III after a mid-stage trial produced encouraging data. No unexpected toxicities were recorded in Phase II that would prevent advancement of the drug, says Point, which saw its stock jump on the news. Report

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.